Thermo Fisher Scientific Inc. $TMO is Guyasuta Investment Advisors Inc.'s 9th Largest Position

Key Points

• Guyasuta Investment Advisors Inc. increased its position in Thermo Fisher Scientific by 5.6% during the second quarter, making it the 9th largest position in their portfolio.
• Thermo Fisher Scientific reported $5.36 earnings per share for the last quarter, surpassing estimates by $0.14, while revenue increased by 2.9% year-over-year.
• The company declared a quarterly dividend of $0.43 per share, translating to a 0.4% annual yield, with the dividend payout ratio at 9.95%.

Guyasuta Investment Advisors Inc. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 109,915 shares of the medical research company's stock after purchasing an additional 5,836 shares during the period. Thermo Fisher Scientific accounts for approximately 2.7% of Guyasuta Investment Advisors Inc.'s portfolio, making the stock its 9th largest position. Guyasuta Investment Advisors Inc.'s holdings in Thermo Fisher Scientific were worth $44,566,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi boosted its holdings in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after buying an additional 329,974 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

TMO stock opened at $464.18 on Friday. The firm has a 50 day moving average price of $476.70 and a 200-day moving average price of $447.57. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The firm has a market capitalization of $175.28 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 2.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last 90 days. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Finally, UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.